05:05 PM EST, 12/19/2024 (MT Newswires) -- Pyxis Oncology ( PYXS ) said late Thursday it will focus its resources on advancing its lead clinical program, PYX-201, as part of its portfolio prioritization plan.

The clinical-stage drugmaker said PYX-201 showed "significant RECIST responses" in head and neck squamous cell carcinoma as well as "additional potential in other solid tumors."

Pyxis said it will suspend further clinical investment in its second clinical program, PYX-106, to allocate resources for PYX-201. PYX-106 was in-licensed from Biosion, with Biosion retaining rights for Greater China.

The company also said its cash position is expected to fund its planned trials of PYX-201 into H2 2026.